news
Long-term potential revealed for novel modifier gene therapy
The positive two-year findings from the Phase I/II gene therapy trial in retinitis pigmentosa reiterate the potential of mutation-agnostic therapies.
List view / Grid view
Retinitis Pigmentosa (RP)
article
Modifier gene therapy – clinical development and manufacturing considerations
Expanding on his earlier podcast discussion with EPR, Dr Arun Upadhyay, Chief Scientific Officer and Head of Research & Development at Ocugen, discusses the company’s promising modifier gene therapy candidates for ophthalmic disorders.
podcasts
EPR Podcast 24 – Developing modifier gene therapy – Ocugen
In this podcast, Dr Neena Haider, Faculty at Harvard Medical School and Dr Arun Upadhyay, Chief Scientific Officer at Ocugen, discuss the development of modifier gene therapy for ocular diseases.
news
ANSM grants authorisation for phase I/II clinical study for retinitis pigmentosa
The French National Agency for Medicines and Health Products Safety is set to launch a Phase I/II clinical trial for HORA-PDE6B, in the treatment of a retinitis pigmentosa...
news
FDA approves cryopreserved formulation of ReNeuron’s candidate
The FDA has approved the cryopreserved formulation of ReNeuron’s human retinal progenitor cell (hRPC) therapeutic candidate...
news
Amarantus forms Elto Pharma for CNS disorders and MANF Therapeutics for ophthalmology
18 April 2017 | By Niamh Marriott, Junior Editor
Amarantus Bioscience has formed a wholly-owned subsidiary named Elto Pharma for the purpose of creating investment vehicles focused exclusively on the further development of Eltoprazine, Amarantus' mid-stage central nervous system (CNS) symptomatic treatment for Adult Attention Deficit and Hyperactivity Disorder (Adult ADHD), Alzheimer's Aggression and Parkinson's disease Levodopa-induced Dyskinesia (PD-LID).
news
NHS England to fund bionic eye surgery
3 January 2017 | By Niamh Louise Marriott, Digital Editor
Surgeons at Manchester and Moorfields Eye Hospital made history by delivering the world’s first trial of the Argus II Bionic Eye implants in RP...
news
MHRA approves bionic vision system clinical trial
31 May 2016 | By Victoria White, Digital Content Producer
Pixium Vision has received approval from the Medicines & Healthcare products Regulatory Agency (MHRA) in the UK to initiate a clinical trial for patients who have lost sight due to retinitis pigmentosa (RP) with the IRIS II bionic vision system.
news
First patient treated in trial of ReNeuron’s retinitis pigmentosa cell therapy
ReNeuron has demonstrated that its Human Retinal Progenitor Cells (hRPCs) improve visual acuity in preclinical models of retinal degeneration...
news
FDA grants Fast Track designation to ReNeuron’s retinitis pigmentosa cell therapy candidate
22 May 2015 | By Victoria White
The US Food and Drug Administration (FDA) has granted Fast Track designation to ReNeuron’s human Retinal Progenitor Cell (hRPC) therapy candidate for retinitis pigmentosa.
news
ReNeuron files application to commence Phase I/II clinical trial with its stem cell therapy candidate for retinitis pigmentosa
13 April 2015 | By Victoria White
ReNeuron has announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to commence a Phase I/II clinical trial with its human Retinal Progenitor Cell (hRPC) therapy candidate for retinitis pigmentosa (RP).
article
Examining receptor activation: New technologies reveal how G protein-coupled receptors recognise ligands and talk to intracellular partners
24 June 2010 | By Thomas P. Sakmar, Laboratory of Molecular Biology & Biochemistry, Rockefeller University
Heptahelical G protein-coupled receptors (GPCRs) are arguably the most important single class of pharmaceutical drug targets in the human genome. According to Overington, of the 266 human targets for approved drugs, a remarkable 27 per cent correspond to rhodopsin-like, or Family A, GPCRs. Despite recent dramatic advances in targeting of…
